Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Pediatrics, Soroka Medical Center, Beer-Sheva, Israel.
PLoS One. 2019 Jul 1;14(7):e0219061. doi: 10.1371/journal.pone.0219061. eCollection 2019.
Opioids constitute a cornerstone of pain relief treatment. However, opioid safety during pregnancy has not been well established. Recent studies reported an association between in utero opioid exposure and spina bifida.
In order to further evaluate the association of opioids exposure during pregnancy with adverse pregnancy outcomes, we conducted a large historical cohort by linking four databases: medications dispensations, births, pregnancy terminations for medical reasons and infant hospitalizations during the years of 1999-2009. Confounders that were controlled for included maternal age, ethnicity, maternal diabetes, smoking status, parity, obesity, year and folic acid intake. A secondary analysis for total major malformations and for spina bifida was performed using propensity score matching for first trimester exposure.
Of the 101,586 women included in the study, 3003 were dispensed opioids during the first trimester. Intrauterine exposure to opioids was not associated with overall major malformations (adjusted odds ratio (aOR) 0.97, 95% CI 0.83-1.13), cardiovascular malformations (aOR = 0.89, 95% CI 0.70-1.13) other malformations by systems or spina bifida in particular. However, the risk for spina bifida among newborns and abortuses who were exposed to codeine was four times higher than that of the unexposed (aOR = 4.42, 95% CI 1.60-12.23). This association remained significant in a secondary analysis using propensity score matching. Third trimester exposure to opioids was not associated with low birth weight (aOR = 1.08, 95% CI 0.77-1.52), perinatal death (aOR = 1.38, 95% CI 0.64-2.99) and other adverse pregnancy outcomes.
These findings suggest that opioids exposure (as a homogenous group) is not a significant risk factor for overall major malformations. Exposure to codeine during the first trimester was found to be associated with increased risk of spina bifida. However, this finding was based on a small number of cases and need to be verified in future work.
阿片类药物是缓解疼痛治疗的基石。然而,妊娠期间阿片类药物的安全性尚未得到充分证实。最近的研究报告称,宫内接触阿片类药物与脊柱裂之间存在关联。
为了进一步评估妊娠期间暴露于阿片类药物与不良妊娠结局之间的关联,我们通过链接四个数据库进行了一项大型历史队列研究:1999 年至 2009 年期间的药物配药、分娩、因医疗原因终止妊娠和婴儿住院。控制的混杂因素包括母亲年龄、种族、母亲糖尿病、吸烟状况、产次、肥胖、年份和叶酸摄入量。使用倾向评分匹配进行了第一次孕期暴露的总主要畸形和脊柱裂的二次分析。
在纳入的 101586 名女性中,有 3003 名在孕早期接受了阿片类药物治疗。宫内接触阿片类药物与总体主要畸形(调整后的优势比(aOR)0.97,95%置信区间(CI)0.83-1.13)、心血管畸形(aOR=0.89,95%CI 0.70-1.13)无相关性,特别是其他畸形系统或脊柱裂。然而,暴露于可待因的新生儿和流产儿发生脊柱裂的风险是未暴露者的四倍(aOR=4.42,95%CI 1.60-12.23)。在使用倾向评分匹配的二次分析中,这种关联仍然显著。孕晚期暴露于阿片类药物与低出生体重(aOR=1.08,95%CI 0.77-1.52)、围产期死亡(aOR=1.38,95%CI 0.64-2.99)和其他不良妊娠结局无关。
这些发现表明,阿片类药物暴露(作为一个同质群体)不是总体主要畸形的显著危险因素。在孕早期接触可待因与脊柱裂风险增加有关。然而,这一发现基于少数病例,需要在未来的工作中进行验证。